Get a Quote

Stiripentol
CAS NO.: 49763-96-4
Chemical Formula: C14H18O3
Molecular Weight: 234.2900
DMF&GMP status: Please contact us for more details.
Description:
Stiripentol is a structurally unique anticonvulsant that has been introduced as adjuvant therapy of Dravet syndrome, a rare form of severe childhood epilepsy. There is limited information on the safety of stiripentol, but it has not been associated with serum aminotransferase elevations or linked to cases of clinically apparent liver injury.

Stiripentol is an anticonvulsant drug used in the treatment of epilepsy as an adjunct therapy along with [DB00349] and [DB00313]. This drug is currently approved in the USA, Canada, and European countries as oral tablets marketed as Diacomit. FDA approval of this drug was granted on August 20, 2018,. Unrelated to other anticonvulsants, stiripentol belongs to the group of aromatic allylic alcohols and may potentiate the effect of other antiepileptic drugs (AEDs) due to pharmacokinetic interactions. It elevates the levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter that regulates electrical activity in the central nervous system.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
STIRIPENTOLCAPSULE;ORAL250MGDIACOMITBIOCODEX SA
STIRIPENTOLCAPSULE;ORAL500MGDIACOMITBIOCODEX SA
STIRIPENTOLFOR SUSPENSION;ORAL250MG/PACKETDIACOMITBIOCODEX SA
STIRIPENTOLFOR SUSPENSION;ORAL500MG/PACKETDIACOMITBIOCODEX SA
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
N.A.N.A.N.A.N.A.N.A.
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 08/20/2023
ODE-198 08/20/2025